What Does the Evidence Really Say About Cannabis Risks and Medical Benefits?

A prominent international research team synthesizes a decade of global evidence on both recreational cannabis harms and medicinal cannabinoid benefits, offering a structured appraisal as cannabis legalization accelerates worldwide and THC potency continues to rise.

Why This Matters

Cannabis policy is shifting faster than the science can settle. As more jurisdictions legalize recreational and medical use, clinicians face patients who assume safety or efficacy that may not be well supported. Meanwhile, THC concentrations in commercial products have climbed substantially over the past decade, raising concerns that earlier epidemiological data may underestimate current risks. A rigorous synthesis of what is actually known, and where uncertainty persists, is essential for responsible clinical guidance at a moment when public messaging often outpaces evidence.

Clinical Summary

This invited narrative review, authored by Hoch, Volkow, Hall, and colleagues and published in the European Archives of Psychiatry and Clinical Neuroscience in 2024, draws on literature indexed in PubMed and Cochrane between 2016 and 2023. It updates a prior German Ministry of Health-commissioned systematic review and covers two broad domains: the health consequences of recreational cannabis use and the efficacy and safety of medicinal cannabinoids. The mechanistic framework centers on THC’s action as a CB1 receptor agonist, which drives dopaminergic signaling in the nucleus accumbens and underlies both its reinforcing properties and its potential for addiction. The authors apply a structured four-criterion causal inference approach, drawing on Bradford Hill principles, to evaluate whether observed associations reflect genuine causal pathways or confounded correlations.

The review finds that regular high-THC cannabis use is associated with cannabis use disorder, cognitive impairment (approximately a 2-point IQ decrement per year of frequent or dependent use onset, largely reversible with abstinence), elevated psychosis risk, mood and anxiety disorders, suicidal behavior, and cardiovascular and respiratory harms, with adolescents and young adults at particular vulnerability. Acute high-dose THC modestly increases traffic accident risk, with odds ratios ranging from 1.25 to 1.97. On the medicinal side, cannabinoids demonstrate small to modest benefits for chronic pain, spasticity, chemotherapy-induced nausea and vomiting, and refractory epilepsy (specifically CBD), while evidence for mental health indications remains inconclusive. Critically, this is a selective rather than systematic review, meaning its conclusions depend on the authors’ choices about which literature to include and emphasize. The full results section of the paper was only partially available for independent analysis, and the authors themselves acknowledge ongoing debate about causal attribution for several mental health outcomes.

Dr. Caplan’s Take

This review does something valuable: it puts recreational harms and medicinal benefits side by side, forcing an honest reckoning with both. Too often, the cannabis conversation is polarized between advocates who minimize risk and opponents who exaggerate it. The mechanistic story linking THC to addiction via CB1 receptors and dopamine signaling is biologically sound, and the adolescent vulnerability data are genuinely concerning. But the gap between association and causation remains real for many of the mental health outcomes discussed here, and a narrative review, however expert, cannot fully close that gap. When patients ask me whether cannabis is safe, the honest answer is that it depends enormously on who is using it, how much, how often, and at what age.

In practice, I counsel patients that high-THC recreational use carries meaningful risks, especially for those under 25 or with personal or family histories of psychotic or mood disorders. For patients exploring medicinal cannabinoids, I am transparent that the strongest evidence supports specific, relatively narrow indications, primarily chronic pain, spasticity, treatment-resistant epilepsy, and chemotherapy-related nausea. I avoid recommending cannabis for anxiety or depression, where the evidence is genuinely inconclusive and the risk of worsening symptoms is not trivial. And I always discuss the real possibility of cannabis use disorder, which remains underappreciated by many patients.

Clinical Perspective

This review sits at a useful but imperfect point in the research arc. It consolidates a substantial body of prior systematic reviews and meta-analyses, lending its conclusions reasonable aggregate weight. It confirms what prior work has established regarding addiction liability, adolescent vulnerability, and the modest efficacy profile of medicinal cannabinoids. However, it does not resolve the causal inference challenges that continue to plague observational cannabis research, particularly for outcomes like psychosis and suicidality where confounding by shared genetic liability, socioeconomic factors, and polysubstance use is difficult to disentangle. Clinicians should treat the associations reported here as credible signals warranting precaution rather than as definitive proof of harm for every outcome discussed.

From a pharmacological standpoint, THC-containing products carry real drug interaction potential, particularly through cytochrome P450 enzyme modulation, and clinicians prescribing medications metabolized by CYP3A4 or CYP2C9 should exercise caution. CBD, used at therapeutic doses for epilepsy, can elevate hepatic transaminases and interact with clobazam and valproate. The cardiovascular signals noted in this review, while not yet definitive, are particularly relevant for older patients or those with pre-existing cardiac risk. One concrete, actionable step: screen all patients reporting cannabis use for frequency, potency, and age of onset, and use those data points to stratify risk in clinical decision-making rather than treating cannabis use as a binary variable.

Study at a Glance

Study Type

Invited narrative review

Population

General population cannabis users, with emphasis on adolescents and young adults; patients using medicinal cannabinoids

Intervention

Recreational cannabis use; medicinal cannabinoid administration

Comparator

Non-users or placebo (varies across cited studies)

Primary Outcomes

Cannabis use disorder, cognitive function, psychosis risk, mood and anxiety disorders, cardiovascular and respiratory health, traffic safety, medicinal efficacy for pain, spasticity, nausea, and epilepsy

Sample Size

Not reported; synthesizes multiple systematic reviews and meta-analyses

Journal

European Archives of Psychiatry and Clinical Neuroscience

Year

2024 (online September 19, 2024; print 2025, vol. 275)

DOI or PMID

Not available in provided materials

Funding Source

Not specified in available text

What Kind of Evidence Is This

This is an invited narrative review, not a formal systematic review. It occupies a middle tier in the evidence hierarchy: above individual expert opinion and below systematic reviews with PRISMA reporting and pre-registered protocols. Its primary evidence base consists of prior systematic reviews and meta-analyses, which lends the synthesis reasonable credibility, but the selective search strategy means that completeness and reproducibility cannot be independently verified, and the weighting of included evidence reflects the authors’ judgment rather than a standardized, transparent process.

How This Fits With the Broader Literature

The findings align closely with the 2017 National Academies of Sciences, Engineering, and Medicine report on cannabis health effects, which similarly identified strong evidence for addiction liability, psychosis risk, and modest medicinal benefit for pain and nausea, while flagging insufficient evidence for many other claimed indications. The cognitive impairment findings are consistent with the Meier et al. (2012) Dunedin cohort study showing IQ decline with persistent adolescent-onset use, though the present review’s acknowledgment of substantial recovery with abstinence tempers the most alarming interpretations of that earlier work. What this review adds is a more current evidence window (through 2023) and explicit engagement with causal inference methodology, though its selective approach means it does not supersede the more methodologically rigorous Cochrane reviews on specific medicinal cannabis indications.

Common Misreadings

The most likely overinterpretation is treating this review as definitive proof that cannabis causes psychosis, depression, or suicidality in a straightforward dose-response manner. The authors themselves note ongoing debate about causal attribution for several mental health outcomes, and much of the underlying evidence is observational, making it vulnerable to residual confounding. A second common misreading runs in the opposite direction: dismissing the medicinal findings as clinically irrelevant because benefits are described as “small to modest.” For patients with refractory chronic pain, treatment-resistant epilepsy, or intractable chemotherapy-induced nausea, even modest effect sizes may represent meaningful clinical improvement when other options have been exhausted.

Bottom Line

This review consolidates credible evidence that regular high-THC cannabis use carries genuine health risks, particularly for adolescents, while medicinal cannabinoids offer real but narrower and more modest benefits than commonly assumed. It does not establish definitive causation for most mental health outcomes, and its selective methodology means it should be read alongside, not in place of, formal systematic reviews. For clinicians, the practical takeaway is to assess cannabis use with the same specificity applied to any pharmacologically active substance: dose, frequency, age of onset, and individual risk factors all matter.

References

1. Hoch E, Volkow ND, Hall W, et al. Health effects of recreational cannabis use and medicinal cannabinoids. European Archives of Psychiatry and Clinical Neuroscience. Published online September 19, 2024. Vol. 275, 2025.
2. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. DOI: 10.17226/24625.
3. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences. 2012;109(40):E2657-E2664. DOI: 10.1073/pnas.1206820109.